By Sarthak Ranade, Managing Director, Janssen India
August 13, 2020
We are pleased to collaborate with Biological E. Limited on the manufacturing of our investigational SARS-CoV-2 vaccine candidate, Ad26.COV2.S. This agreement for the technology transfer of our COVID-19 vaccine candidate to Biological E. further expands our capabilities to deliver on our goal to make our vaccine available to citizens around the world, provided it is proven to be safe and effective.
For more than 70 years, Johnson & Johnson has been advancing healthcare in India, and this proposed collaboration further reinforces the company’s long-standing commitment to India.
India contributes to more than 60% of the global vaccine supply and is well positioned to play a key role in supporting large-scale vaccine production to combat the global pandemic. We are confident that Biological E’s strong vaccine manufacturing experience will assist in the rapid production of a vaccine leveraging Janssen’s proven AdVac® technology beginning in 2021, following approvals from regulators.
Johnson & Johnson also recently announced that a single dose of its vaccine candidate, Ad26.COV2.S, demonstrated robust protection against infection with SARS-CoV-2 in pre-clinical studies. Based on the strength of the data, published in Nature, a Phase 1/2a first-in-human clinical trial of the vaccine candidate in healthy volunteers, has now commenced in the United States and Belgium. The phase 3 clinical trial is expected to commence in September. Simultaneously, Johnson & Johnson is also aiming to rapidly scale up vaccine manufacturing capabilities globally.